Press Releases Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Real-time Estimate Cboe BZX Other stock markets 02:38:10 2024-05-01 pm EDT			5-day change	1st Jan Change
6.17 ^USD	+10.77%		-51.81%	-67.17%

Apr. 30	Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating	MT
Apr. 29	Sector Update: Health Care Stocks Edge Higher Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease	Apr. 29	GL
Annovis Bio : Material Agreement - Form 8-K	Apr. 26	PU
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	Apr. 02	GL
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans	Apr. 01	GL
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Mar. 20	GL
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Mar. 20	AQ
Annovis Bio : Material Event - Form 8-K	Mar. 20	PU
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	Feb. 27	GL
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	Feb. 27	AQ
ANNOVIS BIO ANNOUNCES LAST PATIENT LAST VISIT IN THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER'S DISEASE	Feb. 15	AQ
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Feb. 14	GL
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio	Jan. 30	GL
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio	Jan. 30	AQ
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement	Jan. 24	GL
Annovis Bio to Participate in the 139th Yale CEO Summit	Dec. 11	AQ
Annovis Bio to Participate in the 139th Yale CEO Summit	Dec. 11	GL
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease	Dec. 05	GL
Annovis Bio Appoints Andrew Walsh as Vice President Finance	Dec. 01	GL
Annovis Bio Appoints Andrew Walsh as Vice President Finance	Dec. 01	AQ
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections	Nov. 27	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Press Releases

Filters